Stay updated with breaking news from Recode Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript February 22, 2024 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.46, expectations were $-1.47. Intellia Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome […]
Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.46, expectations were $-1.47. Intellia Therapeutics, Inc.
/PRNewswire/ -- DelveInsight's Global mRNA-based Vaccines and Therapeutics Market Insights report includes a comprehensive understanding of current treatment...
Super-precise gene-editing approach switches off a gene in the liver that regulates ‘bad’ cholesterol. Super-precise gene-editing approach switches off a gene in the liver that regulates ‘bad’ cholesterol.
The US investment firm Bioluminescence Ventures (BLV) has emerged from stealth with $477 million to finance biotech companies developing first-in-class or best-in-class disease treatments.